ITGB1 Antibody

What is ITGB1 and why is it significant in cellular research?

ITGB1, also known as CD29, is a 130 kDa single chain type I glycoprotein that forms heterodimers with various alpha integrin subunits (1-6). It functions as a critical cell adhesion molecule that mediates interactions between cells and the extracellular matrix. ITGB1 is broadly expressed on both hematopoietic and non-hematopoietic cells, including leukocytes, platelets, fibroblasts, endothelial cells, epithelial cells, and mast cells . Its ubiquitous expression and involvement in fundamental cellular processes make it an important target for studying development, wound healing, inflammation, and cancer progression.

ITGB1 is particularly significant because it participates in multiple cellular functions:

• Cell migration and invasion

• Extracellular matrix organization

• Signal transduction

• Cell survival and proliferation

• Tissue architecture maintenance

Understanding ITGB1 expression patterns and functional roles requires specific antibodies that can reliably detect various isoforms and conformational states.

What are the key applications for ITGB1 antibodies in research?

ITGB1 antibodies are employed across diverse experimental approaches to characterize expression, localization, and function. Based on the available technical specifications, the primary applications include:

The selection of an appropriate application should align with specific research questions, such as measuring expression levels (WB, FACS, ELISA), determining localization (IHC, ICC, IF), or investigating protein-protein interactions (IP) .

How does antibody clonality affect ITGB1 detection specificity?

The choice between monoclonal and polyclonal ITGB1 antibodies significantly impacts experimental outcomes due to their inherent differences in epitope recognition and specificity:

Monoclonal Antibodies:

• Recognize a single epitope on the ITGB1 antigen

• Examples include clone MEM-101A (recognizes an extracellular epitope) and 3B6

• Provide consistent lot-to-lot reproducibility

• Offer high specificity but may be sensitive to epitope masking

• Particularly useful for distinguishing specific conformational states of ITGB1

Polyclonal Antibodies:

• Recognize multiple epitopes on the ITGB1 antigen

• Generally provide stronger signals due to binding multiple sites

• Less affected by protein denaturation or fixation conditions

• May exhibit greater batch-to-batch variation

• Can detect multiple isoforms simultaneously

For applications requiring conformation-specific detection (such as activated versus inactive ITGB1), monoclonal antibodies targeting specific epitopes are preferable. When maximum sensitivity is needed, particularly with partially degraded samples, polyclonal antibodies may yield better results .

What are the major isoforms of ITGB1 and their tissue distribution patterns?

ITGB1 exists in multiple isoforms with distinct tissue distribution patterns and functional implications:

When studying ITGB1, researchers should consider which isoforms are relevant to their specific tissue or cell type of interest. This consideration is crucial for antibody selection, as certain antibodies may preferentially recognize specific isoforms depending on their epitope location .

What are the critical validation steps for ITGB1 antibodies in experimental workflows?

Rigorous validation is essential for ensuring reliable ITGB1 antibody performance across different applications. A comprehensive validation strategy should include:

1. Positive and Negative Controls:

• Positive controls: Cell lines with known ITGB1 expression (HT-1080, Hela, A431 for human; C6 for rat)

• Negative controls: ITGB1 knockout cells or tissues

• Cross-reactivity assessment with related integrins

2. Epitope Mapping:

• Determine the exact binding region (e.g., extracellular domain, cytoplasmic domain)

• Consider how epitope location affects detection in different applications

• Assess epitope conservation across species for cross-reactivity studies

3. Application-Specific Validation:

• For Western blot: Confirm expected molecular weight (88-140 kDa depending on glycosylation)

• For flow cytometry: Compare with established ITGB1 antibody clones

• For immunostaining: Verify subcellular localization patterns

• For functional studies: Test effects on integrin-mediated adhesion or signaling

4. Reproducibility Assessment:

• Test multiple antibody lots

• Evaluate consistency across different sample preparation methods

• Document performance across experimental replicates

Proper validation ensures that experimental observations reflect true biological phenomena rather than antibody artifacts or non-specific binding .

How can researchers optimize ITGB1 immunoblotting to detect specific isoforms?

Detecting specific ITGB1 isoforms via Western blotting requires careful optimization of sample preparation and electrophoresis conditions:

Sample Preparation Considerations:

• Cell lysis buffer selection is critical - RIPA buffers may denature conformational epitopes

• Include appropriate protease inhibitors to prevent degradation

• Control phosphorylation status by including phosphatase inhibitors

• Optimize protein loading (30 μg is typically used for cell lysates)

Electrophoresis and Transfer Parameters:

• Gradient gels (5-20% SDS-PAGE) improve separation of different molecular weight isoforms

• Extended running times at lower voltage (70-90V) enhance separation

• Semi-dry transfer may be optimal for larger proteins like ITGB1

• Use PVDF membranes for better protein retention and stronger signals

Detection Optimization:

• Blocking with 5% non-fat milk in TBS for 1.5 hours at room temperature

• Primary antibody concentration between 0.25-0.5 μg/ml

• Overnight incubation at 4°C improves specific binding

• HRP-conjugated secondary antibodies at 1:5000 dilution

• Enhanced chemiluminescent detection systems provide optimal sensitivity

Expected bands: The canonical form appears at approximately 88 kDa under reducing conditions, with glycosylated forms appearing between 115-140 kDa. Different isoforms may show slight molecular weight variations that can be detected with high-resolution electrophoresis .

What are the optimal fixation and permeabilization protocols for ITGB1 immunofluorescence studies?

Successful immunofluorescence detection of ITGB1 requires careful consideration of fixation and permeabilization methods to preserve epitope accessibility while maintaining cellular architecture:

Fixation Options and Considerations:

Permeabilization Strategies:

• For paraformaldehyde-fixed cells: 0.1-0.3% Triton X-100 (5-10 minutes)

• For methanol-fixed cells: Additional permeabilization often unnecessary

• For detecting activated ITGB1 conformations: Gentler permeabilization with 0.1% saponin

Epitope Retrieval Considerations:
For formalin-fixed paraffin-embedded tissues, heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) for 20 minutes may be necessary to expose ITGB1 epitopes.

The optimal protocol depends on whether the target epitope is extracellular (like that recognized by MEM-101A clone) or intracellular, as well as the specific conformation of interest .

What strategies can address common troubleshooting issues in ITGB1 flow cytometry?

Flow cytometric analysis of ITGB1 can present several technical challenges that require specific troubleshooting approaches:

1. Low Signal Intensity:

• Increase antibody concentration (start with 1 μg per million cells)

• Extend incubation time (30-45 minutes at 4°C)

• Use fluorophores with higher quantum yield (PE conjugates often provide superior sensitivity for ITGB1 detection)

• Ensure cells remain viable throughout processing

• Add sodium azide (0.05%) to prevent antibody internalization

2. High Background/Non-specific Binding:

• Optimize blocking (2% BSA or 5-10% serum from secondary antibody species)

• Include Fc receptor blocking reagents for hematopoietic cells

• Use isotype controls matched to primary antibody

• Implement stringent washing steps (3x with excess buffer)

• Titrate antibody to determine optimal concentration

3. Inconsistent Staining Patterns:

• Standardize cell preparation protocols (enzymatic detachment can cleave ITGB1)

• Use mechanical dissociation methods when possible

• Maintain consistent buffer composition and pH

• Process samples consistently (time and temperature)

• Consider fixation effects on epitope accessibility

4. Detecting Conformational Changes:

• Use conformation-specific antibodies

• Maintain physiological calcium levels (1-2 mM) during processing

• Control temperature throughout the procedure

• Consider kinetics of activation/inactivation

PE-conjugated antibodies, like the MEM-101A clone, often provide excellent sensitivity for ITGB1 detection in flow cytometry applications due to the high fluorophore-to-protein ratio and significant brightness of the PE fluorochrome .

How can ITGB1 expression be effectively quantified across different experimental conditions?

Accurate quantification of ITGB1 expression requires selecting appropriate methodologies based on experimental requirements and available resources:

1. Relative Quantification Methods:

2. Absolute Quantification Approaches:

• ELISA using recombinant ITGB1 standards (0.1-0.5 μg/ml antibody concentration)

• Mass spectrometry with isotope-labeled peptide standards

• Flow cytometry with quantitative beads (molecules of equivalent soluble fluorochrome)

3. Quantification Workflow Optimization:

• Establish linear dynamic range for each assay

• Include multiple biological and technical replicates

• Implement appropriate statistical analysis

• Consider temporal dynamics of expression

4. Experimental Design Considerations:

• Account for cell confluence effects on integrin expression

• Control for matrix composition influences

• Consider cell cycle stage impacts

• Document passage number for cell lines

For comparing ITGB1 expression across diverse experimental conditions, it is advisable to employ multiple complementary techniques to validate findings and minimize method-specific biases .

What are the current approaches for studying ITGB1 conformational changes during integrin activation?

Integrin activation involves conformational changes that transition ITGB1 from a bent (inactive) to an extended (active) conformation. Several specialized approaches enable researchers to investigate these dynamic conformational states:

1. Conformation-Specific Antibodies:

• Antibodies that specifically recognize active ITGB1 conformations

• Epitope-specific antibodies that differentially bind to regulatory regions

• Comparative analysis with pan-ITGB1 antibodies (like MEM-101A)

2. Microscopy-Based Approaches:

• FRET-based biosensors for monitoring ITGB1 activation in real-time

• Super-resolution microscopy to visualize nanoscale conformational changes

• Live-cell imaging with activation-specific antibodies

3. Biochemical Techniques:

• Limited proteolysis to assess accessibility of cleavage sites

• Crosslinking studies to capture transient conformational states

• Blue native PAGE to preserve native protein complexes

4. Functional Assays:

• Ligand binding assays with purified proteins

• Cell adhesion strength measurements

• Inside-out vs. outside-in signaling assessments

5. Computational Approaches:

• Molecular dynamics simulations of conformational transitions

• Structural modeling based on cryo-EM and crystallography data

• Quantitative analysis of binding kinetics

When studying ITGB1 activation states, it is crucial to maintain physiological conditions (temperature, divalent cation concentrations, pH) throughout experimental procedures to prevent artificial activation or inactivation of the integrin complexes.

How do different blocking strategies impact signal-to-noise ratio in ITGB1 immunodetection?

Blocking is a critical step that significantly influences ITGB1 antibody specificity and sensitivity across various applications:

Blocking Agent Comparison for ITGB1 Detection:

Optimization Guidelines:

• For Western blot: 5% non-fat milk in TBS for 1.5 hours at room temperature has been validated for ITGB1 detection

• For immunofluorescence: 10% normal serum with 1% BSA for 30-60 minutes

• For flow cytometry: 2% BSA with Fc receptor blocking for 10-15 minutes

Impact on ITGB1-Specific Signal:

• Insufficient blocking leads to high background, especially in tissues with abundant extracellular matrix

• Excessive blocking can mask low-abundance epitopes

• Blocking time and temperature influence antibody penetration and binding kinetics

When working with glycosylated forms of ITGB1, it may be necessary to avoid milk-based blockers that contain glycoproteins which could interfere with antibody recognition of carbohydrate-modified epitopes .

What considerations are important when selecting ITGB1 antibodies for studying protein-protein interactions?

Investigating ITGB1 interactions with binding partners requires careful antibody selection to avoid interference with interaction domains:

Critical Selection Factors:

• Epitope Location:

  • Antibodies targeting non-interaction domains preserve natural binding events

  • Consider whether the epitope is accessible in protein complexes

  • Antibodies against the extracellular domain (like MEM-101A) may be preferable for capturing intact complexes

• Antibody Format:

  • Native-preserving applications benefit from non-denaturing conditions

  • Consider using F(ab')₂ fragments to eliminate Fc receptor interactions

  • Biotinylated antibodies for gentle elution conditions

• Validation for Specific Techniques:

• Control Strategies:

  • Use multiple antibodies targeting different ITGB1 epitopes

  • Include isotype controls for non-specific binding assessment

  • Implement competitive binding controls with recombinant domains

• Technical Considerations:

  • Detergent selection impacts complex stability (mild non-ionic detergents preserve interactions)

  • Buffer composition affects conformation (divalent cations for active integrin states)

  • Temperature management during isolation procedures

When studying ITGB1-alpha integrin heterodimers, antibodies that recognize epitopes away from the alpha-beta interface are essential to maintain native interactions .

How can researchers effectively study ITGB1 in three-dimensional cell culture systems?

Three-dimensional culture systems provide physiologically relevant contexts for studying ITGB1 function but present unique methodological challenges:

Sample Preparation Approaches:

• Fixation and Preservation:

  • Extend fixation times (4% PFA, 30-45 minutes) for complete penetration

  • Consider hydrogel-specific fixatives for maintaining 3D architecture

  • Implement gentler permeabilization to preserve delicate structures

• Antibody Penetration Strategies:

  • Extended incubation times (overnight at 4°C)

  • Increased antibody concentrations (2-3× higher than 2D cultures)

  • Use of smaller antibody fragments or nanobodies for dense matrices

  • Sequential multi-day immunostaining protocols

• Imaging Considerations:

  • Confocal microscopy with appropriate Z-stack parameters

  • Light sheet microscopy for larger spheroids/organoids

  • Tissue clearing techniques (CLARITY, CUBIC, iDISCO) for deep imaging

  • Quantitative 3D image analysis workflows

Analytical Approaches:

Validation Strategies:

• Compare 2D vs 3D expression patterns and localization

• Implement ITGB1 functional blocking in 3D systems

• Correlate with in vivo findings when possible

• Use multiple antibody clones to confirm specificity

When examining ITGB1 in 3D cultures, researchers should be particularly attentive to the spatial organization of integrin complexes at the cell-matrix interface, which often differs significantly from 2D culture patterns.

How does ITGB1 antibody selection differ for clinical versus research applications?

ITGB1 antibody requirements vary substantially between clinical diagnostics and basic research contexts:

Comparative Requirements:

Application-Specific Selection Criteria:

• For Research:

  • Epitope specificity aligned with experimental questions

  • Compatibility with multiple applications (multi-purpose)

  • Performance in model systems (mouse, rat, etc.)

  • Detection of specific activation states or isoforms

• For Clinical Applications:

  • Extensively validated for diagnostic accuracy

  • Consistent performance in FFPE human tissues

  • Compatible with standard clinical workflows

  • Established cutoff values and scoring systems

The selection of appropriate ITGB1 antibodies should be guided by the specific research or clinical question, with careful consideration of the validation data provided by manufacturers and peer-reviewed literature .

What are the key considerations for using ITGB1 antibodies in multicolor flow cytometry panels?

Incorporating ITGB1 antibodies into multicolor flow cytometry panels requires strategic planning to optimize detection and minimize interference:

Panel Design Considerations:

• Fluorophore Selection:

  • PE-conjugated ITGB1 antibodies offer excellent sensitivity for major populations

  • APC conjugates provide good separation in complex panels

  • Consider brightness hierarchy (assign brighter fluorophores to lower-expression targets)

• Channel Selection and Spectral Overlap:

  • Place ITGB1 detection in channels with minimal spillover from other markers

  • Implement proper compensation controls (single-stained controls)

  • Consider using spectral cytometry for complex panels

• Titration and Optimization:

  • Determine optimal antibody concentration for each specific conjugate

  • Test different antibody clones for compatibility with other panel components

  • Validate performance in relevant biological contexts

Sample Preparation Protocol:

Controls and Quality Assessment:

• Fluorescence-minus-one (FMO) controls to set accurate gates

• Isotype controls matched to ITGB1 antibody

• Biological controls (positive and negative for ITGB1 expression)

• Daily quality control with standardized beads

When designing multicolor panels including ITGB1, researchers should consider the activation state of interest, as certain stimuli or isolation procedures may alter integrin conformation and affect antibody binding .